Natera, Inc. announced the broad clinical availability of its ultra-sensitive Signatera Genome assay to physicians across the United States. This new molecular residual disease (MRD) test is designed to provide enhanced detection capabilities for circulating tumor DNA (ctDNA).
The launch is supported by a large genome-based MRD study, which was accepted for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This study involved over 3,000 samples from multiple cancer types, validating the assay's performance.
Signatera Genome leverages Natera’s patented multiplex polymerase chain reaction and next-generation sequencing technology, allowing it to detect tiny traces of tumor DNA at frequencies as low as 1 part per million. This ultra-sensitivity aims to improve patient management by enabling earlier and more precise detection of residual disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.